Get Involved

AMMF’s Hybrid 2022 European 
Cholangiocarcinoma Conference

All presentations from AMMF’s 3-day European Cholangiocarcinoma Conference held 11-13 May 2022 are now available here to watch again.  Simply click on the topic title to see that presentation. 

Poster presentations are available here

Day 1 Day 2 Day 3
Topic Presenter
WELCOME – DAY 3
Co-chairs’ welcome to DAY 3 Professor Jesus Bañales
Biodonostia Institute, Spain
Nottingham – Introduction to the CCA work At Nottingham Professor Kevin Gaston
University of Nottingham
AMMF Supported Research – “Investigating the role of Interleukin 17 (IL-17) in tumour lymphangiogenesis in CCA” Dr Isioma Egbuniwe
University of Nottingham
“Identifying new drug combinations for the in vitro inhibition of cholangiocarcinoma cell growth Professor Sheela Jayaraman
University of Nottingham
QUESTION TIME Nottingham panel
Liverpool – Introduction to the CCA work at Liverpool. A triumvirate of clinical service development, training and research, defining A centre of expertise Mr Hassan Malik
Aintree University Hospital
AMMF Supported Research – Identification of actionable targets in peri hilar CCA using whole exome sequencing Dr Timothy Gilbert
University of Liverpool
“Developing an ex-vivo tissue model of CCA using precision” Dr Laura Randle
Liverpool John Moores University
QUESTION TIME Liverpool Panel
Edinburgh and Glasgow- Scotland – Introduction of Cholangiocarcinoma in Scotland – combining efforts between Edinburgh and Glasgow Dr Luke Boulter
University of Edinburgh
AMMF Supported Research: “Using patient led genetics to define new therapeutic targets in intrahepatic cholangiocarcinoma” Dr Luke Boulter
University of Edinburgh
“Modelling the earliest moments of CCA formation and the interface of liver damage and genetic mutation” Dr Ed Jarman
University of Edinburgh
QUESTION TIME Edinburgh panel
AMMF SUPPORTED RESEARCH continued
“The role of normal cholangiocytes in regulating cholangiocarcinoma cells during co-culture” Gemma Owen
University of Oxford
“The virus-driven intrahepatic CCA” Dr Stephen Griffin
University of Leeds
“Role of the transcription factor KLF5 in the etiopathogenesis of CCA: New diagnostic prognostic and therapeutic strategy” Dr Pedro Rodrigues
Biodonostia Institute, Spain
QUESTION TIME Research Panel
LOOKING TO THE FUTURE
The way ahead… Helen Morement, AMMF
Artificial intelligence guide to treatment and Q&A Dr Shirin E Khorsandi
Kings’ college hospital, London
Organoid and Animal models: Seminar and Q&A Dr Chiara Braconi
University of Glasgow
Dr Luke Boulter
University of Edinburgh
Conference closing Professor Juan Valle
University of Manchester and
The Christie

Professor Jesus Bañales
Biodonostia Institute, Spain

Helen Morement, AMMF
Back to previous page